122852-42-0

122852-42-0 structure

Name: Alosetron
Chemical Name: alosetron
CAS Number: 122852-42-0
Molecular Formula: C₁₇H₁₈N₄O
Molecular Weight: 294.35100
Catalog: API Digestive system medication Laxative antidiarrheal
Create Date: 2018-09-16 13:50:30
Modify Date: 2024-01-02 13:57:14
Alosetron is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.IC50 Value: Target: 5-HT ReceptorAlosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia.

Name	alosetron
Synonyms	UNII-13Z9HTH115 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one Alosetron HCl

Description	Alosetron is a Serotonin 5HT3-receptor antagonist that is used in treatment of irritable bowel syndrome.IC50 Value: Target: 5-HT ReceptorAlosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT3 antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT3 receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT3 antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Neurological Disease
References	[1]. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome By Harris, Lucinda A.; Chang, Lin From Women's Health (2007), 3(1), 15-27. [2]. Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 20 [3]. Lucak S. Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron. Therap Adv Gastroenterol. 2012 Jul;5(4):215-8. [4]. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D severity criteria. Curr Med Res Opin. 2012 Mar;28(3):449-56.

Density	1.34 g/cm3
Boiling Point	648.1ºC at 760 mmHg
Molecular Formula	C₁₇H₁₈N₄O
Molecular Weight	294.35100
Flash Point	345.8ºC
Exact Mass	294.14800
PSA	53.92000
LogP	2.34620
Vapour Pressure	1.1E-16mmHg at 25°C
Index of Refraction	1.706
Storage condition	2-8℃

Hazard Codes	Xi
Risk Phrases	R36/37/38
Safety Phrases	S26-S36

106147-85-7

122852-75-9

122852-42-0

Literature: US5221687 A1, ;

38585-62-5

122852-75-9

~28%

122852-42-0

Literature: AUSPEX PHARMACEUTICALS, INC. Patent: US2010/113478 A1, 2010 ; Location in patent: Page/Page column 13 ;

550340-81-3

122852-75-9

~63%

122852-42-0

Literature: ORCHID CHEMICALS and PHARMACEUTICALS LIMITED Patent: US2012/178937 A1, 2012 ; Location in patent: Page/Page column 3 ;

38585-62-5

144-55-8

122852-75-9

122852-42-0

Literature: US5196534 A1, ; US 5196534 A

Precursor 5
106147-85-7 122852-75-9 38585-62-5 550340-81-3
144-55-8
DownStream 0

122852-42-0	1190043-13-0
132414-02-9	122852-69-1
122852-75-9	1189919-71-8
122852-43-1